1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Title:

Reasons for non-attendance to cervical cancer screening and acceptability of HPV self-sampling among Bruneian women: A cross-sectional study.

Authors:

Liling Chaw^{1*}, Shirley HF Lee¹, Nurul Iffah Hazwani Ja’afar¹, Edwin Lim², Roslin Sharbawi³

Affiliations:

- 1) PAPRSB Institute of Health Sciences, Gadong, Brunei Darussalam.
- 2) Histopathology Department, RIPAS Hospital, Ministry of Health, Brunei Darussalam
- 3) Community Maternal Health Service, Department of Health Services, Ministry of Health, Bandar Seri Begawan, Brunei Darussalam

*** Corresponding Author:**

Email: liling.chaw@ubd.edu.bn (LC)

Running title:

Reasons for cervical cancer screening non-attendance and HPV self-sampling acceptability in Brunei

Number of words: 327 words (abstract), 3049 words (manuscript, excluding references)

26

27 Abstract

28

29 **Objective:** Uptake for cervical cancer screening remains well below the recommended rate of 80%.

30 We conducted a preliminary study to determine the reasons for non-attendance and explore their
31 acceptance of human papillomavirus (HPV) self-sampling as an alternative to the Pap test.

32

33 **Methods:** A cross-sectional study was conducted at a health center in Brunei, from January to
34 December 2019. Women who were eligible for Pap test but who either never or did not have one
35 within the past four years were conveniently recruited. Participants were first asked to complete a
36 paper-based survey on their reasons for screening non-attendance, and then invited for HPV self-
37 sampling. Results were analyzed using descriptive and inferential statistics.

38

39 **Result:** We enrolled 174 screening non-attendees, out of which 97 (55.7%) also participated in HPV
40 self-sampling. The main reasons for not attending Pap test screening were fear of bad results
41 (16.1%, n = 28); embarrassment (14.9%, n = 26) and lack of time due to home commitments (10.3%,
42 n = 18). When compared to those who agreed to participate in HPV self-sampling, those who
43 declined were significantly older ($p = 0.002$) and less likely to agree that they are susceptible to
44 cervical cancer ($p = 0.023$). They preferred to receive Pap test-related information from healthcare
45 workers (59.0%, n = 155), social messaging platforms (28.7%, n = 51) and social media (26.4%, n =
46 47). HPV self-sampling kits were positively received, where > 90% agreed on its ease and
47 convenience. Nine of 97 participants (9.3%) tested positive for hr-HPV, out of which eight were non-
48 16/18 HPV genotypes.

49

50 **Conclusion:** Our findings suggest that promoting knowledge on cervical cancer, the benefits of
51 screening and clarifying any misconceptions of Pap test results would help increase screening uptake

52 among Bruneian non-attendees. Response to HPV self-sampling was highly positive, implying its
 53 receptiveness in the local setting. Our high detection of non-16/18 HPV genotypes suggest high
 54 prevalence of other hr-HPV genotypes in Brunei. Larger studies can be conducted to further validate
 55 our findings.

56

57

58

59 **Keywords:** Cervical cancer screening, HPV self-sampling, women's health, Brunei

60 Introduction

61

62 Cervical cancer is highly preventable but still remains one of the most common cancers among
63 women worldwide, accounting for 6.6% of all female cancer deaths in 2018 [1]. Cervical cancer
64 screening has drastically reduced the incidence of invasive cervical cancer in countries that have
65 implemented such screening programs [2], which traditionally involves the use of the standard
66 Papanicolaou (Pap) test. However, as specific high-risk human papillomavirus subtypes (hr-HPV) are
67 known to be a causative agent, the use of HPV self-sampling is becoming either an alternative or a
68 complement to Pap test, with an aim to increase screening uptake rate [3] particularly among
69 screening non-attendees [4].

70

71 HPV self-sampling were found to be highly acceptable among screening non-attendees [5,6].
72 Repeated HPV self-sampling and testing were shown to increase screening uptake [3,4,7], and also
73 resulted in at least two-fold higher detection rate of high-grade cervical intraepithelial neoplasia
74 (CIN2+) when compared to the Pap test [8,9]. In addition, HPV self-sampling results exhibit similar
75 sensitivity and specificity compared to those from samples taken by trained professionals [10]. At
76 the national level, early detection through organized screening was shown to reduce cervical cancer
77 morbidity and mortality in countries such as the United Kingdom and Australia [11,12]. Both
78 countries have further strengthened their national screening programs by using HPV testing as the
79 primary screening test.

80

81 Brunei Darussalam (population 459,500) is a small Southeast Asian country with a predominant
82 Muslim population and a crude birth rate of 15.3 per 1,000 population [13]. Within this region, it has
83 one of the highest age-standardized incidence rate (ASR) for cervical cancer: 20.6 in Brunei when
84 compared to 10.5 and 7.7 in Malaysia and Singapore, respectively [14]. Brunei has initiated a
85 national cervical cancer prevention and control program since 2009, which include setting up the

86 National Pap Test Registry, organizing cervical screening through periodic mail invitations for eligible
87 women, replacing the Pap test with liquid-based cytology, and initiating HPV vaccination for school-
88 aged female adolescents [15]. However, despite cervical screening being offered free of charge, the
89 national screening coverage rate remains low at 44% in 2018 (unpublished data). It is known that
90 screening non-attendees are at increased risk of developing cervical cancer [16], and that reasons
91 for screening non-attendance can also vary across settings [17,18].

92

93 With Brunei's relatively high incidence of cervical cancer and low screening uptake, we conducted a
94 preliminary study to explore the reasons behind non-attendance and to assess the acceptability of
95 HPV self-sampling as a possible alternative to the Pap test among non-attendees. Study findings
96 could be used to strategize ways to improve screening uptake and provide preliminary evidence
97 towards implementing HPV testing as the primary screening test for cervical cancer in Brunei.

98

99 Methods

100

101 Study design and data collection

102

103 A cross-sectional survey was conducted at the Jubli Perak Sengkurong Health Center (JPSHC), from
104 January to December 2019. JPSHC is a government-funded health center located at Brunei-Muara
105 District, where the majority (69.3%) of the country's population resides. This center provides primary
106 health care services to Mukim Sengkurong, a sub-district with about 32 000 people from various
107 socioeconomic backgrounds.

108

109 Eligible women attending either the outpatient or child health clinic were conveniently recruited by
110 triage nurses. The inclusion criteria were married or ever married Bruneian women between 20 and
111 65 years old, who either never or did not have a Pap test within the last 4 years, and who can

comprehend Brunei-Malay or English language. We excluded women who were pregnant, have had total hysterectomy, or with a history of malignancies.

Participants who gave written consent to the first part of the study were asked to complete the first questionnaire (Q1) onsite. They were then given an envelope containing information on the second part and an instruction leaflet on the HPV self-sampling procedure. Upon second contact about two weeks later, those who gave verbal consent were given an appointment to JPSHC. On the day, a trained nurse first explained the procedure using an instructional video and answered any questions. Participants who gave another written consent were then given a self-sampling kit and asked to perform the procedure in the clinic. After completion, they were asked to complete the second questionnaire (Q2).

Questionnaires used

Two bilingual paper-based questionnaires (Brunei-Malay and English language) were used: one on the reasons for non-attendance (Q1) and another on their acceptability of the self-sampling procedure (Q2). Both questionnaires were adapted from similar studies [19,20]. They were first translated to Brunei-Malay language by native speakers, and then back-translated to check for inconsistencies in comprehension. Both questionnaires were also pre-tested on six eligible women to assess if the questions can be easily understood. Responses from pre-testing were not included in the main analysis.

Q1 consists of 19 questions on the participant's socio-demographics; reasons for not getting Pap test; attitude and knowledge on cervical cancer; and lastly, preferred sources to acquire information about Pap test. From a prepared list of 16 options, participants were asked to select one ("Major" reason) or more reasons (categorized as "Minor" reasons) for not attending the screening program.

Responses for questions on their attitude and knowledge on cervical cancer were assessed using a five-point Likert scale, ranging from “Strongly Agree” to “Strongly Disagree”. Q2 consists of 12 five-point Likert scale questions (ranging from “Strongly Agree” to “Strongly Disagree”) on their experiences and opinions of the self-sampling kit.

Self-sample handling and laboratory testing

Swabs collected from the self-sampling kits were sent to an overseas laboratory (at BNH hospital, Thailand) for hr-HPV testing. The self-sampling device used was the Evalyn® brush from Rovers Medical Devices. Upon receipt at the testing laboratory, the dry Evalyn® brush was suspended in SurePath medium from which a sample was obtained for the identification of the presence of hr-HPV using the cobas HPV test (Roche, USA). Cobas HPV tests are automated qualitative *in vitro* tests for the detection of HPV DNA in patient specimens. The tests utilize amplification of target DNA by polymerase chain reaction (PCR) and nucleic acid hybridization for the detection of 14 hr-HPV types (namely genotypes 16, 18, and 12 pooled hr-HPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a single analysis. Results obtained from this test can be categorized into four groups: Negative, HPV-16 positive, HPV-18 positive, and positive for non-16/18 HPV genotypes.

Clinical management of hr-HPV positive participants

We adopted the cytology triage strategy for HPV self-sampling participants [21]. Participants with hr-HPV positive results were invited for an immediate clinic-based cytology triage test. Those found to have negative cytology results were invited for a repeat cytology triage test after six months. Those with second negative results were returned to routine cervical screening recall. Participants with any positive cytology result (defined as with Atypical Squamous Cells of Undetermined Significance or worse) were referred for colposcopic examination.

Statistical analysis

Descriptive statistics was conducted to characterize the socio-demographic characteristics of the study population, their reasons for not attending screening, their attitudes and preference for information access on such screening, as well as responses from Q2. Mann-Whitney and Fisher's exact tests were used to assess significant differences in sociodemographic characteristics between women who agreed and women declined to proceed to the HPV self-sampling part of the study. Responses for questions with the five-point Likert scale were categorized into three categories (agree, neutral, and disagree), and those with missing values were classified as neutral. Statistical analysis was conducted using R ver. 3.6 [22]. Ethics approval was obtained from the Medical and Health Research and Ethics Committee (MHREC), Ministry of Health, Brunei Darussalam [Reference no. MHREC/MOH/2018/9(2)].

Results

A total of 174 eligible women were enrolled into the study from January to December 2019, out of which 97 (55.7%) also participated in HPV self-sampling (Fig. 1). Their median age was 45 years, ranging between 23 and 65 years (Table 1). The participants were mainly of Malay ethnicity (92.5%, $n = 161$), married (90.2%, $n = 157$), and had ≥ 3 births (60.3%, $n = 105$). About half of the participants had their last Pap test performed between 4 and 10 years ago (52.3%, $n = 91$), and have never received the HPV vaccine (54.6%, $n = 95$). There were significant differences between those who agreed and declined to participate in HPV self-sampling: those who declined were significantly older ($p = 0.002$) and more likely to have their last Pap test performed > 10 years ago ($p = 0.031$).

Fig 1. Flowchart of study participants at JPHSC, Brunei (Jan – Dec 2019).

190 Table 1. Sociodemographic characteristics of the study population, including comparison between
191 groups that agreed and declined to join HPV self-sampling. IQR = Interquartile range.

192

Characteristics		Total study population (n = 174) n (%)	Joined self-sampling (n = 97) n (%)	Declined self-sampling (n = 77) n (%)	p-value
Median age in years (IQR)		45.0 (15.25)	41.0 (17)	49.0 (14.5)	0.002*
Age-group (in years)	20 - 24	3 (1.7)	3 (3.1)	0 (0.0)	0.018*
	25 - 29	20 (11.5)	15 (15.5)	5 (6.5)	
	30 - 34	14 (8.1)	10 (10.3)	4 (5.2)	
	35 - 39	28 (16.1)	18 (18.5)	10 (13.0)	
	40 - 44	18 (10.3)	11 (11.3)	7 (9.0)	
	45 - 49	27 (15.5)	12 (12.4)	15 (19.5)	
	50 - 54	35 (20.1)	15 (15.5)	20 (26.0)	
	55 - 59	14 (8.1)	10 (10.3)	4 (5.2)	
	> 60	13 (7.5)	3 (3.1)	10 (13.0)	
	Missing	2 (1.1)	0 (0.0)	2 (2.6)	
Race	Malay	161 (92.5)	90 (92.8)	71 (92.2)	0.752
	Chinese	6 (3.5)	4 (4.1)	2 (2.6)	
	Other	7 (4.0)	3 (3.1)	4 (5.2)	
Education level	Primary school	16 (9.2)	10 (10.3)	6 (7.8)	0.396
	Secondary school	96 (55.2)	49 (50.5)	47 (61.0)	
	College / University	57 (32.7)	35 (36.1)	22 (28.6)	
	Missing	5 (2.9)	3 (3.1)	2 (2.6)	
Marital status	Married	157 (90.2)	91 (93.8)	66 (85.7)	0.15
	Divorced	8 (4.6)	2 (2.1)	6 (7.8)	
	Widowed	9 (5.2)	4 (4.1)	5 (6.5)	
Occupation	Housewife	64 (36.8)	39 (40.2)	25 (32.4)	0.087
	Government employee	67 (38.5)	41 (42.3)	26 (33.8)	
	Private employee	31 (17.8)	13 (13.4)	18 (23.4)	
	Retired	9 (5.2)	3 (3.1)	6 (7.8)	
	Unemployed	1 (0.6)	1 (1.0)	0 (0.0)	
	Other	2 (1.1)	0 (0.0)	2 (2.6)	
Monthly household income	< \$500	27 (15.5)	15 (15.5)	12 (15.6)	0.498
	\$500 < \$999	27 (15.5)	12 (12.4)	15 (19.5)	
	\$1000-\$1999	40 (23.0)	22 (22.7)	18 (23.4)	
	\$2000-\$2999	19 (10.9)	14 (14.3)	5 (6.5)	
	\$3000-\$5000	24 (13.8)	15 (15.5)	9 (11.7)	
	>\$5000	3 (1.7)	2 (2.1)	1 (1.3)	
	Missing	34 (19.5)	17 (17.5)	17 (22.0)	
Number of births	0	27 (15.5)	17 (17.5)	10 (13.0)	0.103
	1	19 (10.9)	14 (14.4)	5 (6.5)	

	2	22 (12.1)	14 (14.4)	7 (9.1)	
	3 or more	105 (60.3)	51 (52.6)	54 (70.1)	
	Missing	2 (1.2)	1 (1.1)	1 (1.3)	
Last Pap test done	Never	41 (23.6)	29 (29.9)	12 (15.6)	0.031*
	4-10 years	91 (52.3)	48 (49.5)	43 (55.8)	
	> 10 years	36 (20.7)	15 (15.5)	21 (27.3)	
	Missing	6 (3.4)	5 (5.1)	1 (1.3)	
Completed HPV vaccination	Never	95 (54.6)	50 (51.6)	45 (58.4)	0.483
	Yes	27 (15.5)	16 (16.5)	11 (14.3)	
	No	41 (23.6)	26 (26.8)	15 (19.5)	
	Missing	11 (6.3)	5 (5.1)	6 (7.8)	

193

194 Fig. 2 and S1 Table show the responses for the major and minor reasons for not attending cervical
195 cancer screening. The top three major reasons reported were that they were “afraid of getting a bad
196 result” (16.1%, n = 28), “feeling embarrassed being examined by a doctor or nurse” (14.9%, n = 26),
197 and “I can't find the time as I'm too busy at home” (10.3%, n = 18). The top three minor reasons
198 were “feeling embarrassed being examined by a doctor or nurse” (20.7%, n = 36), “I can't find time
199 as I'm too busy at work” (20.7%, n = 36), and “afraid of getting a bad result” (20.1%, n = 35).

200

201 Fig. 2. Responses on their major and minor reasons for not attending cervical cancer screening,
202 among non-attendees at JPSHC (Jan – Dec 2019). The x-axis indicates the percentage, and the
203 number next to each bar indicates the actual number of responses.

204

205 When comparing top 10 major reasons for not attending screening between those who agreed and
206 declined HPV self-sampling (Table 2), those whose major reason was “feeling embarrassed being
207 examined by a doctor or nurse” were significantly more likely to join self-sampling ($p = 0.020$). Also,
208 those whose major reason was “afraid of getting a bad result” were significantly more likely to
209 decline self-sampling ($p = 0.034$). Among those who were employed (n = 98), about a quarter (23.5%,
210 n = 23) reported work-related reasons as their major reason for not attending screening (“I can't find
211 the time as I'm too busy at work” and “Difficult to get permission from employer”).

Table 2. The top ten major reasons of not attending cervical cancer screening at JPSHC, Brunei (Jan – Dec 2019), with comparison between those who agreed and declined HPV self-sampling. Responses from 146 participants (83.9% of the total study population) were included.

No.	Top ten major reasons of screening non-attendance	Total n (%)	Joined HPV self-sampling n (%)	Declined HPV self-sampling n (%)	p-value
1	I feel embarrassed being examined by a doctor or nurse	26 (14.9)	20 (76.9)	6 (23.1)	0.020*
2	I am scared of pain because of previous bad experience(s)	16 (9.2)	8 (50.0)	8 (50.0)	0.825
3	I am scared of getting a bad result	28 (16.1)	10 (35.7)	18 (64.3)	0.034*
4	I can't find the time as I'm too busy at home	18 (10.3)	12 (66.7)	6 (33.3)	0.463
5	I can't find the time as I'm too busy at work	16 (9.2)	10 (62.5)	6 (37.5)	0.759
6	Difficult to get permission from employer	8 (4.6)	5 (62.5)	3 (37.5)	1
7	I have never heard of a Pap Test	7 (4.0)	4 (57.1)	3 (42.9)	1
8	I have forgotten about it	6 (3.4)	5 (83.3)	1 (16.7)	0.229
9	I did not receive any invitation	6 (3.4)	5 (83.3)	1 (16.7)	0.229
10	Others	15 (8.6)	7 (46.7)	8 (53.3)	0.492

While the responses vary when asked about their health and susceptibility to disease, most agreed on the benefits of undergoing Pap test (92.0%, n = 160), and on the severity of cervical cancer (82.8%, n = 144; Table 3 and S2 Table). Those who agreed that they are more susceptible to develop cervical cancer were significantly more likely to join HPV self-sampling ($p = 0.023$).

Table 3. Attitudes towards cervical cancer screening among non-attendees at JPSHC, Brunei (Jan– Dec 2019), between those who agreed and declined HPV self-sampling.

No.	Attitude questions		Total study population (n = 174) n (%)	Joined HPV self-sampling (n = 97) n (%)	Declined HPV self-sampling (n = 77) n (%)	p-value
1	I believe I am healthy and free of any diseases	Agree	62 (35.6)	34 (54.8)	28 (45.2)	0.984
		Neutral/ Disagree	112 (64.3)	63 (56.3)	49 (43.7)	
2	Having Pap test taken is beneficial for my health	Agree	160 (92.0)	91 (56.9)	69 (43.1)	0.464
		Neutral/ Disagree	14 (8.0)	6 (42.9)	8 (57.1)	
3	Like any women, I am susceptible to develop cervical cancer	Agree	110 (63.2)	69 (62.7)	41 (37.3)	0.023*
		Neutral/ Disagree	64 (36.8)	28 (43.8)	36 (56.2)	
4	Cervical cancer can be severe and may lead to death	Agree	144 (82.8)	79 (54.9)	65 (45.1)	0.754
		Neutral/ Disagree	30 (17.2)	18 (60.0)	12 (40.0)	

227

228

229 Most participants would like to obtain more information about cervical cancer screening (85.6%, n =

230 149). The top preferred information sources were healthcare workers (59.8%, n = 104), social

231 messaging platforms (28.7%, n = 50) and social media (26.4%, n = 46; S1 Fig).

232

233 Among those who participated in self-sampling (55.7%, n = 97), their responses on Q2 (Table 4) were

234 generally positive and encouraging. A majority agreed that the instructions were clear (94.8%, n =

235 92), that it was easy to perform the swab (93.8%, n = 91), and that it was more convenient than the

236 Pap test (91.7%, n = 89). They also reported their confidence in correctly getting the sample (92.8%,

237 n = 90), would prefer to use this method next time (94.8%, n = 92), and would recommend this

238 method to other women (93.8%, n = 91). Notably, 54.6% (n = 53) still prefer a proper Pap test for

239 their subsequent check-up.

240

241 Table 4. Acceptability of HPV self-sampling among non-attendees who participated in HPV self-

242 sampling at JPSHC, Brunei (Jan–Dec 2019). Responses from all Q2 respondents (n = 97) were

243 included.

244

No.	Self-sampling Questions	Agree n (%)	Neutral n (%)	Disagree n (%)
1	I thought the instructions were clear	92 (94.8)	0 (0.0)	5 (5.2)
2	It was easy to do the swab	91 (93.8)	1 (1.0)	5 (5.2)
3	Taking the sample with the swab was painful	12 (12.4)	8 (8.2)	77 (79.4)
4	Taking the sample was uncomfortable to do	11 (11.4)	4 (4.1)	82 (84.5)
5	I felt embarrassed doing the self-sampling	9 (9.3)	1 (1.0)	87 (89.7)
6	It was convenient to do without having to undergo a Pap Test	89 (91.7)	3 (3.1)	5 (5.2)
7	I am confident I did it correctly	90 (92.8)	4 (4.1)	3 (3.1)
8	I want to use this method next time	92 (94.8)	2 (2.1)	3 (3.1)
9	I prefer to do this at home	64 (66.0)	15 (15.5)	18 (18.5)
10	I would recommend this method to other women	91 (93.8)	3 (3.1)	3 (3.1)
11	I trust that the result of this self-sampling will be accurate	74 (76.3)	19 (19.6)	4 (4.1)
12	I would like to attend for a proper Pap test in clinic next time	53 (54.6)	23 (23.7)	21 (21.7)

Among the 97 samples taken, nine (9.3%) tested positive for hr-HPV: one was positive for HPV 16 and eight were positive for non-HPV 16/18 HPV genotype. Upon follow-up cytology, only one participant had a normal cytological test result, whilst another participant with non-16/18 HPV genotype was found to have CIN 3 with glandular involvement following a confirmatory biopsy. No significant differences were observed when comparing the sociodemographic characteristics between those who tested hr-HPV positive and those who tested hr-HPV negative (S3 Table).

Discussion

This preliminary cross-sectional study explored the reasons for cervical screening non-attendance among Bruneian women, and whether HPV self-sampling is a viable alternative for the non-attendees. Our findings highlight three important points to consider for improving screening uptake and cervical cancer detection.

260

261 First, our findings suggest that it is necessary to provide accurate information among Bruneian
262 women on cervical cancer, the importance of screening and addressing any misconceptions about
263 the Pap test. Important facts to relay include the slow development from pre-cancerous changes to
264 cervical cancer, that pre-cancerous changes are highly treatable, and that screening will help in early
265 detection and thus facilitate successful treatment.

266

267 In our study, emotional barriers (fear of unfavorable test results and embarrassment) were the most
268 common major reasons of screening non-attendance. Also, about two-thirds of our participants
269 cited “I am scared of getting a bad result” as their main barrier also declined to take part in HPV self-
270 sampling, possibly due to relating abnormal Pap test results to cervical cancer diagnoses [23].

271 Although such barriers may play a large role at the onset of screening program, its role diminishes
272 over time with increasing education on the benefits of screening [24]. Educational interventions
273 could also benefit the small group of women who cited menopause, cessation of child-bearing and
274 having had HPV vaccination as reasons for not attending screening.

275

276 In our study, we observed those who agree that they are susceptible to cervical cancer were
277 significantly more likely to participate in HPV self-sampling. This suggests that perceived
278 susceptibility could be an important factor for self-sampling participation, whereby those who do
279 not perceive themselves as susceptible were less likely to engage in preventative behaviors [25–27].

280 Perceived susceptibility can be increased through education to improve their beliefs on the
281 importance of screening [28]. We suggest that such information could be more effectively
282 disseminated as simple health messages endorsed by Brunei’s Ministry of Health via website and
283 social media platforms.

284

Second, we observed high acceptability of HPV self-sampling among our participants. Meta-analyses have indicated strong acceptance of and preference for self-sampling over clinician sampling [29], mainly due to logistical reasons [30]. More than half of our participants who joined HPV self-sampling cited embarrassment or lack of time due to home and/or work commitments as their major reason of not attending Pap test screening. This suggest that providing flexibility to accommodate women's screening method preference [31], such as the option of self-sampling [32], could improve screening uptake.

Thirdly, most of the detected hr-HPV genotypes in our study were non-16/18, with only one out of nine participants tested positive for HPV 16. Although our sample size is small, this result suggests that it may not be accurate to assume HPV 16 or 18 as common hr-HPV genotypes in Brunei, even though this is true in the global context [33]. Other studies have detected a significant percentage of non-16/18 hr-HPV genotypes, suggesting the presence of region-specific heterogeneity in the HPV genotype distribution [33–37]. Also, variation in HPV distribution among different ethnic groups has been reported in an American study [38]. Our finding has potential implication on Brunei's national school-based HPV vaccination program which currently provides vaccines which do not confer protection against non-16/18 genotypes. Larger population-based studies to understand the distribution of HPV genotypes among Bruneian women will be crucial to determine the efficacy or impact of the current vaccines.

One notable point for the local context relates to the presence of cultural barriers. Being a predominantly Islamic society, religious and cultural modesty could be a contributing factor for embarrassment among Muslim women [39]. Also, having premarital sex is a cultural taboo in Brunei and is generally not openly discussed [40]. This could prevent any unmarried but sexually active women from participating in the screening program. It should be emphasized that only married or

ever married females were included in this study; included because it is part of the eligibility criteria for the national cervical cancer screening program in Brunei.

A major limitation for this study is that non-attendees from only one health center were recruited, thus our findings are not representative of the adult female population in Brunei. Secondly, our findings should also be interpreted with caution due to the small sample size and the non-probability sampling approach used. This study was initially conceived as a preliminary study due to resource and logistics limitations. There were two reasons for choosing JPSHC as our study site: It is the third largest primary government healthcare center in the country, and that it serves a sub-district with a sizable percentage of residents in the middle- to low-income groups. It is hoped that even at this preliminary stage, our study findings could encourage stakeholders to conduct similar and larger studies, using random sampling approach. Lastly, as this study relied on the self-reported history of previous Pap test attendance, we might have missed recruiting those who may have forgotten their last Pap test date.

In conclusion, our findings indicate the need to further promote knowledge on cervical cancer, the benefits of screening and clarifying any misconceptions of Pap test results. Reasons of cervical cancer screening non-attendance were mainly related to emotional and logistical factors. As we found high acceptance towards HPV self-sampling, this could be adopted as an alternative for women who refrain from Pap test. Our high detection of non-16/18 HPV genotypes suggest high prevalence of other hr-HPV genotypes in Brunei. Future larger studies involving more Bruneian women should be done to verify our results. Follow-up studies should also be conducted to consider HPV testing as the suitable method for cervical cancer screening.

Acknowledgements

336 The authors would like to thank the JPSHC staff who have assisted in participant recruitment and
337 questionnaire distribution.

338

339

340

References

1. World Health Organization. Cervical cancer. [cited 8 Sep 2020]. Available: https://www.who.int/health-topics/cervical-cancer#tab=tab_1
2. Gustafsson L, Pontén J, Zack M, Adami H-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. *Cancer Causes Control*. 1997;8: 755–763. doi:10.1023/A:1018435522475
3. Yeh PT, Kennedy CE, Vuyst H de, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. *BMJ Glob Heal*. 2019;4: e001351. doi:10.1136/BMJGH-2018-001351
4. CS R, DR W, D G. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. *Can J Public Health*. 2013;104. doi:10.1007/BF03405681
5. Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, et al. Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. *Prev Med (Baltim)*. 2018. doi:10.1016/j.ypmed.2018.06.017
6. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Retraite L Le, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: A randomized study among cervical screening nonattenders from lower socioeconomic groups in France. *Int J Cancer*. 2013. doi:10.1002/ijc.28283
7. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): A population-based cluster-randomised trial. *Lancet Glob Heal*. 2015;3: e85–e94. doi:10.1016/S2214-109X(14)70354-7
8. Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand A-S, Sanner K, et al. Randomised study shows that repeated self-sampling and HPV test has more than two-fold

367 higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer.
368 2018;118: 896–904. doi:10.1038/bjc.2017.485

369 9. Arrossi S, Paolino M, Laudi R, Gago J, Campanera A, Marín O, et al. Programmatic human
370 papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in
371 Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob
372 Heal. 2019. doi:10.1016/S2214-109X(19)30048-8

373 10. Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening
374 programs in Europe: The transition towards HPV vaccination and population-based HPV
375 testing. Viruses. 2018;10. doi:10.3390/v10120729

376 11. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer
377 mortality: Estimation using stage-specific results from a nested case-control study. Br J
378 Cancer. 2016;115: 1140–1146. doi:10.1038/bjc.2016.290

379 12. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: Comparison of
380 screening policy and uptake, and cancer incidence and mortality. Med J Aust. 2006;185: 482–
381 486. doi:10.5694/j.1326-5377.2006.tb00661.x

382 13. Ministry of Health Brunei Darussalam. Health Information Booklet 2017 (Second Revision).
383 2019 [cited 11 Feb 2020]. Available: [http://moh.gov.bn/SitePages/Health Information](http://moh.gov.bn/SitePages/Health%20Information%20Booklet.aspx)
384 [Booklet.aspx](http://moh.gov.bn/SitePages/Health%20Information%20Booklet.aspx)

385 14. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of
386 incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal.
387 2020;8: e191–e203. doi:10.1016/S2214-109X(19)30482-6

388 15. Chaw LL, Lim STW, Md Yussof SR. Human Papillomavirus vaccine coverage among female
389 students in Brunei Darussalam: results from the first 4 years of the national school-based
390 vaccination programme. Heliyon. 2019;5. doi:10.1016/j.heliyon.2019.e02588

391 16. Peto PJ, Gilham PC, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has
392 prevented in the UK. Lancet. 2004;364: 249–256. doi:10.1016/S0140-6736(04)16674-9

- 393 17. Bosgraaf RP, Ketelaars PJW, Verhoef VMJ, Massuger LFAG, Meijer CJLM, Melchers WJG, et al.
394 Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in
395 Dutch women. *Prev Med (Baltim)*. 2014. doi:10.1016/j.ypmed.2014.04.011
- 396 18. , Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences among non-
397 attendees to cervical screening. *Gynecol Oncol*. 2014. doi:10.1016/j.ygyno.2014.09.019
- 398 19. Bayu H, Berhe Y, Mulat A, Alemu A. Cervical Cancer Screening Service Uptake and Associated
399 Factors among Age Eligible Women in Mekelle Zone, Northern Ethiopia, 2015: A Community
400 Based Study Using Health Belief Model. *PLoS One*. 2016;11: e0149908.
401 doi:10.1371/journal.pone.0149908
- 402 20. Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, et al. Women's experience
403 with home-based self-sampling for human papillomavirus testing. *BMC Cancer*. 2015;15: 849.
404 doi:10.1186/s12885-015-1804-x
- 405 21. The Hague: Health Council of the Netherlands. Health Council of the Netherlands Population
406 screening for cervical cancer. 2011;2011/07E. Available:
407 https://www.gezondheidsraad.nl/sites/default/files/201107E_PopulationSCC_0.pdf
- 408 22. R Core Team. R: A language and environment for statistical computing. R Foundation for
409 Statistical Computing, Vienna, Austria; 2020. Available: <http://www.r-project.org/>
- 410 23. Fylan F. Screening for cervical cancer: a review of women's attitudes, knowledge, and
411 behaviour. *Br J Gen Pract*. 1998;48: 1509–14.
- 412 24. Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, et al.
413 Understanding the role of embarrassment in gynaecological screening: A qualitative study
414 from the ASPIRE cervical cancer screening project in Uganda. *BMJ Open*. 2014.
415 doi:10.1136/bmjopen-2014-004783
- 416 25. Agurto I, Arrossi S, White S, Coffey P, Dzuba I, Bingham A, et al. Involving the community in
417 cervical cancer prevention programs. *Int J Gynaecol Obstet*. 2005;89 Suppl 2: S38-45.
418 doi:10.1016/j.ijgo.2005.01.015

- 419 26. Shirazi Zadeh Mehraban S, Namdar A, Naghizadeh MM. Assessment of Preventive Behavior
420 for Cervical Cancer with the Health Belief Model. Asian Pac J Cancer Prev. 2018;19: 2155–
421 2163. doi:10.22034/APJCP.2018.19.8.2155
- 422 27. Tapera R, Manyala E, Erick P, Maswabi TM, Tumoyagae T, Letsholo B, et al. Knowledge and
423 Attitudes towards Cervical Cancer Screening amongst University of Botswana Female
424 Students. Asian Pac J Cancer Prev. 2017;18: 2445–2450. doi:10.22034/APJCP.2017.18.9.2445
- 425 28. Khademolhosseini F, Noroozi A, Tahmasebi R. The Effect of Health Belief Model-Based
426 Education through Telegram Instant Messaging Services on Pap smear performance. Asian
427 Pac J Cancer Prev. 2017;18: 2221–2226. doi:10.22034/APJCP.2017.18.8.2221
- 428 29. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled
429 screening for HPV DNA: A systematic review and meta-analysis. Sexually Transmitted
430 Infections. 2017. doi:10.1136/sextrans-2016-052609
- 431 30. Lorenzi NPC, Termini L, Longatto Filho A, Tacla M, de Aguiar LM, Beldi MC, et al. Age-related
432 acceptability of vaginal self-sampling in cervical cancer screening at two university hospitals:
433 a pilot cross-sectional study. BMC Public Health. 2019. doi:10.1186/s12889-019-7292-1
- 434 31. Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection
435 sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. BMC
436 Public Health. 2014;14: 596. doi:10.1186/1471-2458-14-596
- 437 32. Jeronimo J, Perkins RB, Scalici J, Pierce JY. Should Self-Sampling Be an Option for Women in
438 the United States? J Low Genit Tract Dis. 2019;23: 54. doi:10.1097/LGT.0000000000000453
- 439 33. Albawardi A, Quddus MR, Al Awar S, Almarzooqi S. Frequency of rare and multi viral high-risk
440 HPV types infection in cervical high grade squamous intraepithelial lesions in a non-native
441 dominant middle eastern country: A polymerase chain reaction-based pilot study. Diagn
442 Pathol. 2018. doi:10.1186/s13000-018-0716-x
- 443 34. Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and Genotype Distribution of
444 HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China’s Largest CAP

445 Certified Laboratory. J Cancer. 2016. doi:10.7150/jca.14971

446 35. Khoo SP, Bhoo-Pathy N, Yap SH, Anwar Shafii MK, Hairizan Nasir N, Belinson J, et al.

447 Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV)

448 carriage in a cross-sectional, multiethnic, community-based female Asian population. Sex

449 Transm Infect. 2018. doi:10.1136/sextrans-2017-053320

450 36. Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of

451 cervical human papillomavirus infection among female sex workers in Asia: A systematic

452 literature review and meta-analysis. Sexual Health. 2012. doi:10.1071/SH11066

453 37. Al-Awadhi R, Chehadeh W, Jaragh M, Al-Shaheen A, Sharma P, Kapila K. Distribution of

454 human papillomavirus among women with abnormal cervical cytology in Kuwait. Diagn

455 Cytopathol. 2013. doi:10.1002/dc.21778

456 38. Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessel NA, Anastos K, et al. Racial differences in

457 human papilloma virus types amongst United States women with HIV and cervical precancer.

458 AIDS. 2018. doi:10.1097/QAD.0000000000002005

459 39. Ali S, Skirton H, Clark MT, Donaldson C. Integrative review of cervical cancer screening in

460 Western Asian and Middle Eastern Arab countries. Nurs Heal Sci. 2017;19: 414–426.

461 doi:10.1111/nhs.12374

462 40. Haji Tahamit N. Cultural and Religious Barriers to Setting Up Sex and Relationship Education

463 in a Muslim Country: A Case Study of Brunei Darussalam. University of Leeds; 2015 Aug.

464 Available: <https://etheses.whiterose.ac.uk/15306/>

465

466

467

Supplementary information

S1 Table. Responses on their major and minor reasons for not attending cervical cancer screening

among non-attendees at JPSHC, Brunei (Jan – Dec 2019).

S2 Table. Attitudes towards cervical cancer screening among non-attendees at JPSHC, Brunei (Jan –

Dec 2019). Responses from the total study population (n = 174) were included.

S1 Fig. Preferred sources of information about cervical cancer among non-attendees at JPSHC,

Brunei (Jan–Dec 2019). The x-axis indicates the percentage, and the number next to each bar

indicates the number of responses. Multiple responses were allowed and responses from the total

study population (n = 174) were included.

S3 Table. Socio demographic characteristics and comparison between screening non-attendees who

tested positive and negative for hr-HPV at JPSHC, Brunei (Jan – Dec 2019).

S4 Questionnaire. Questionnaire 1: Reasons why women do not participate in the National Cervical

Cancer Screening Program

S5 Questionnaire. Questionnaire 2: Acceptability of Self Sampling for HPV Testing Among Non-

attendees of Cervical Screening Program in Brunei Darussalam

S6 Dataset. Minimal dataset

497

498

499 **Author contributions:**

500 **Liling Chaw:** Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Writing -

501 original draft, Writing - review & editing

502 **Shirley HF Lee:** Visualization, Writing - original draft, Writing - review & editing

503 **Nurul Iffah Hazwani Ja'afar:** Investigation, Data curation, Writing - original draft

504 **Edwin Lim:** Conceptualization, Methodology, Resources, Funding acquisition, Supervision, Writing -

505 review & editing

506 **Roslin Sharbawi:** Conceptualization, Methodology, Resources, Funding acquisition, Investigation,

507 Project administration, Supervision, Writing - original draft, Writing - review & editing

508